Canada · Delayed Price · Currency is CAD NeuPath Health Statistics
Total Valuation
NeuPath Health has a market cap or net worth of CAD 33.15 million. The enterprise value is 43.10 million.
| Market Cap | 33.15M |
| Enterprise Value | 43.10M |
Important Dates
The last earnings date was Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuPath Health has 56.18 million shares outstanding. The number of shares has increased by 5.35% in one year.
| Current Share Class | 56.18M |
| Shares Outstanding | 56.18M |
| Shares Change (YoY) | +5.35% |
| Shares Change (QoQ) | +5.47% |
| Owned by Insiders (%) | 3.73% |
| Owned by Institutions (%) | 10.98% |
| Float | 49.23M |
Valuation Ratios
The trailing PE ratio is 3,682.96 and the forward PE ratio is 7.61.
| PE Ratio | 3,682.96 |
| Forward PE | 7.61 |
| PS Ratio | 0.37 |
| PB Ratio | 1.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 21.30 |
| P/OCF Ratio | 13.71 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.21, with an EV/FCF ratio of 27.70.
| EV / Earnings | 4,788.96 |
| EV / Sales | 0.48 |
| EV / EBITDA | 9.21 |
| EV / EBIT | 17.64 |
| EV / FCF | 27.70 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.11 |
| Quick Ratio | 1.05 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 2.80 |
| Debt / FCF | 8.41 |
| Interest Coverage | 3.11 |
Financial Efficiency
Return on equity (ROE) is 1.38% and return on invested capital (ROIC) is 3.91%.
| Return on Equity (ROE) | 1.38% |
| Return on Assets (ROA) | 3.49% |
| Return on Invested Capital (ROIC) | 3.91% |
| Return on Capital Employed (ROCE) | 7.50% |
| Weighted Average Cost of Capital (WACC) | 8.07% |
| Revenue Per Employee | 587,947 |
| Profits Per Employee | 59 |
| Employee Count | 152 |
| Asset Turnover | 2.04 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NeuPath Health has paid 312,000 in taxes.
| Income Tax | 312,000 |
| Effective Tax Rate | 51.57% |
Stock Price Statistics
The stock price has increased by +125.00% in the last 52 weeks. The beta is 1.06, so NeuPath Health's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +125.00% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 0.45 |
| Relative Strength Index (RSI) | 62.73 |
| Average Volume (20 Days) | 221,363 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeuPath Health had revenue of CAD 89.37 million and earned 9,000 in profits. Earnings per share was 0.00.
| Revenue | 89.37M |
| Gross Profit | 16.91M |
| Operating Income | 2.44M |
| Pretax Income | 605,000 |
| Net Income | 9,000 |
| EBITDA | 3.40M |
| EBIT | 2.44M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 3.54 million in cash and 13.09 million in debt, with a net cash position of -9.56 million or -0.17 per share.
| Cash & Cash Equivalents | 3.54M |
| Total Debt | 13.09M |
| Net Cash | -9.56M |
| Net Cash Per Share | -0.17 |
| Equity (Book Value) | 21.32M |
| Book Value Per Share | 0.37 |
| Working Capital | 1.34M |
Cash Flow
In the last 12 months, operating cash flow was 2.42 million and capital expenditures -862,000, giving a free cash flow of 1.56 million.
| Operating Cash Flow | 2.42M |
| Capital Expenditures | -862,000 |
| Depreciation & Amortization | 952,000 |
| Net Borrowing | -2.10M |
| Free Cash Flow | 1.56M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 18.92%, with operating and profit margins of 2.73% and 0.01%.
| Gross Margin | 18.92% |
| Operating Margin | 2.73% |
| Pretax Margin | 0.68% |
| Profit Margin | 0.01% |
| EBITDA Margin | 3.80% |
| EBIT Margin | 2.73% |
| FCF Margin | 1.74% |
Dividends & Yields
NeuPath Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.35% |
| Shareholder Yield | -5.35% |
| Earnings Yield | 0.03% |
| FCF Yield | 4.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuPath Health has an Altman Z-Score of 1.86 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.86 |
| Piotroski F-Score | 6 |